David Buchebner

MD. PhD, specialised in Endochrinology

David Buchebner, MD, PhD, is a specialist in endocrinology. He is Quality Assurance Manager at Yazen Health and contributes with scientific expertise in endocrinology and metabolic disease.

Orange stylized human head with colorful flowers and vines growing out from the top and back.

David Buchebner, MD, PhD, is a physician specialised in endocrinology. He completed his doctoral studies in osteoporosis research at Lund University and holds a medical degree from the Medical University of Vienna.

His main scientific interests include osteoporosis, vitamin D, overweight and obesity, and the internal medicine aspects of endocrinology. David has combined many years of clinical work with research-driven development at Hallands Hospital Halmstad and within Region Halland.

Since 2024, he has served as Quality Assurance Manager at Yazen Health, where his expertise in endocrinology and metabolic disease supports the development of evidence-based care.

Articles by

David Buchebner

Science and publications

High Adherence to GLP-1 Receptor Agonists: 18-Month Outcomes from the Yazen Model

High adherence rates to GLP-1 receptor agonists within a structured, digitally based weight management programme, may contribute to improved long-term medication adherence.
‍

Summary‍

This real-world analysis from Yazens first large scale operational quality follow-up, demonstrates almost 70% compliance with GLP-1 medications at 12 months, surpassing earlier studies that showed 20-50%^1-4. After 2 years*, 60% of patients were still in treatment.

© 2025 Yazen. All rights reserved.

Yazen Health AB operates as a registered healthcare provider under the General Data Protection Regulation (GDPR), the Swedish Health and Medical Care Act, Patient Data Act, and the Patient Security Act. Our proprietary systems, including the patient app and electronic medical record (EMR) system, are officially registered with the Swedish Health and Social Care Inspectorate (IVO).

Featured news & articles

Featured news & articles

David Buchebner

Articles by

David Buchebner

High Adherence to GLP-1 Receptor Agonists: 18-Month Outcomes from the Yazen Model

High adherence rates to GLP-1 receptor agonists within a structured, digitally based weight management programme, may contribute to improved long-term medication adherence.
‍

Summary‍

David Buchebner

Articles by

David Buchebner

High Adherence to GLP-1 Receptor Agonists: 18-Month Outcomes from the Yazen Model

High adherence rates to GLP-1 receptor agonists within a structured, digitally based weight management programme, may contribute to improved long-term medication adherence.‍

Summary‍

High adherence rates to GLP-1 receptor agonists within a structured, digitally based weight management programme, may contribute to improved long-term medication adherence.
‍